Shanghai, Wuhan, November 12, 2021: Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen (Chinese Name).

Montreal, Shanghai, Wuhan, November 4, 2021: Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. (hereinafter referred to as “SPH”, 601607.SH; 2607.HK) for in vivo applications. This licensing agreement is limited to the greater China market.

Montreal, Shanghai, Wuhan, October 11, 2021: Phagelux, Inc. is proud to announce the trademark filing of LysiThru, our novel high through put screening system for rapidly developing lysins effective against both gram positive and gram negativebacteria.

Jan.16, 2020 Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.